PL373246A1 - Zastosowanie ligandów receptora EP4 do leczenia chorób związanych z IL-6 - Google Patents

Zastosowanie ligandów receptora EP4 do leczenia chorób związanych z IL-6

Info

Publication number
PL373246A1
PL373246A1 PL03373246A PL37324603A PL373246A1 PL 373246 A1 PL373246 A1 PL 373246A1 PL 03373246 A PL03373246 A PL 03373246A PL 37324603 A PL37324603 A PL 37324603A PL 373246 A1 PL373246 A1 PL 373246A1
Authority
PL
Poland
Prior art keywords
treatment
receptor ligands
involved diseases
diseases
involved
Prior art date
Application number
PL03373246A
Other languages
English (en)
Inventor
Masato Shimojo
Kana Taniguchi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL373246A1 publication Critical patent/PL373246A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL03373246A 2002-04-12 2003-04-03 Zastosowanie ligandów receptora EP4 do leczenia chorób związanych z IL-6 PL373246A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37236402P 2002-04-12 2002-04-12

Publications (1)

Publication Number Publication Date
PL373246A1 true PL373246A1 (pl) 2005-08-22

Family

ID=29250846

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373246A PL373246A1 (pl) 2002-04-12 2003-04-03 Zastosowanie ligandów receptora EP4 do leczenia chorób związanych z IL-6

Country Status (18)

Country Link
US (2) US7148234B2 (pl)
EP (1) EP1499305A2 (pl)
JP (1) JP2005533756A (pl)
KR (1) KR100592007B1 (pl)
CN (2) CN100579518C (pl)
AU (1) AU2003214525B2 (pl)
BR (1) BR0309200A (pl)
CA (1) CA2481535C (pl)
IL (1) IL164263A0 (pl)
MX (1) MXPA04009243A (pl)
MY (1) MY140867A (pl)
NO (1) NO20044462L (pl)
NZ (1) NZ535748A (pl)
PL (1) PL373246A1 (pl)
RU (1) RU2285527C2 (pl)
TW (1) TW200409636A (pl)
WO (1) WO2003086371A2 (pl)
ZA (1) ZA200407795B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1996012503A1 (en) * 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
HU225539B1 (en) * 1998-03-17 2007-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR101020350B1 (ko) * 2003-03-13 2011-03-08 이데미쓰 고산 가부시키가이샤 신규한 질소 함유 헤테로환 유도체 및 이를 이용한 유기 전기발광 소자
CA2566094A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
ES2344310T3 (es) * 2005-03-11 2010-08-24 Raqualia Pharma Inc Formas cristalinas de un derivado de imidazol.
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008071736A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
CN101622229B (zh) 2007-02-26 2013-02-27 参天制药株式会社 具有脲基和氨基羰基作为取代基的吡咯衍生物
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
WO2009064431A1 (en) * 2007-11-15 2009-05-22 Eisai E & D Management Co., Ltd. Methods of use
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
CN102131774A (zh) 2008-08-25 2011-07-20 参天制药株式会社 含有脲基、氨基羰基及可以具有取代基的二环式基团作为取代基的新型吡咯衍生物
CA2768315A1 (en) 2009-07-17 2011-01-20 Novozymes A/S A method of analyzing cellulose decay in cellulosic material hydrolysis
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
ES2574253T3 (es) * 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
CA2788548A1 (en) 2010-01-29 2011-08-04 Novozymes A/S Biogas production process with enzymatic pre-treatment
MX341482B (es) * 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
WO2011126897A2 (en) 2010-03-30 2011-10-13 Novozymes A/S Methods for enhancing by-products from fermentation processes
WO2012018775A1 (en) 2010-08-02 2012-02-09 Novozymes North America, Inc. Process of producing a fermentation product
WO2012044758A1 (en) * 2010-09-29 2012-04-05 The Procter & Gamble Company Methods of synthesizing 2-methoxymethyl-1,4-benzenediamine
BR112013012357A2 (pt) 2010-11-19 2016-10-11 Novozymes North America Inc processos de produzir um produto de fermentação, de produzir um açúcar, de produzir uma dextrina e de produzir sacarose, e, composição
KR101952981B1 (ko) 2011-07-07 2019-02-27 구미아이 가가쿠 고교 가부시키가이샤 니트로벤젠 화합물의 제조방법
US9550724B2 (en) 2011-12-14 2017-01-24 Ihara Chemical Industry Co., Ltd. Diphenylamine compounds and production method thereof
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
CN105189447B (zh) 2013-06-25 2017-12-05 组合化学工业株式会社 制造硝基苯化合物的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
WO2015134792A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
WO2015143144A1 (en) 2014-03-19 2015-09-24 Novozymes A/S Method for enhancing activity of an x143 polypeptide
US9343949B2 (en) * 2014-09-22 2016-05-17 Texas Instruments Incorporated Control circuit to detect a noise signal during a state change of a switch
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
WO2017195619A1 (ja) 2016-05-09 2017-11-16 クミアイ化学工業株式会社 ニトロベンゼン化合物を製造する方法
WO2017207340A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN113135920A (zh) 2016-06-30 2021-07-20 株式会社大熊制药 吡唑并嘧啶衍生物作为激酶抑制剂
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
WO2021163400A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
CN116478155B (zh) * 2022-01-17 2025-06-13 洛阳惠中兽药有限公司 一种格拉匹伦及其中间体的制备方法
EP4626884A1 (en) 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
CN116496274A (zh) * 2023-05-10 2023-07-28 江苏天和制药有限公司 一种ep4受体拮抗剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536507A (en) * 1977-07-26 1985-08-20 Merck & Co., Inc. Prostaglandin antagonists
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
CA2197091A1 (en) * 1994-08-08 1996-02-22 Fusao Ueda Triazine derivative and medicine
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000054808A1 (fr) * 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives

Also Published As

Publication number Publication date
ZA200407795B (en) 2007-01-31
RU2004130320A (ru) 2005-06-10
HK1076737A1 (en) 2006-01-27
CN100579518C (zh) 2010-01-13
WO2003086371A3 (en) 2004-06-03
KR100592007B1 (ko) 2006-06-21
MXPA04009243A (es) 2005-06-08
IL164263A0 (en) 2005-12-18
TW200409636A (en) 2004-06-16
CN1658847A (zh) 2005-08-24
BR0309200A (pt) 2005-02-22
NO20044462L (no) 2005-01-11
AU2003214525B2 (en) 2008-09-25
AU2003214525A1 (en) 2003-10-27
CA2481535C (en) 2010-08-17
NZ535748A (en) 2007-06-29
MY140867A (en) 2010-01-29
KR20040105864A (ko) 2004-12-16
CN101023946A (zh) 2007-08-29
CA2481535A1 (en) 2003-10-23
RU2285527C2 (ru) 2006-10-20
WO2003086371A2 (en) 2003-10-23
US7928119B2 (en) 2011-04-19
US20070066618A1 (en) 2007-03-22
JP2005533756A (ja) 2005-11-10
US20030236260A1 (en) 2003-12-25
US7148234B2 (en) 2006-12-12
EP1499305A2 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
ZA200407795B (en) Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
GB0307918D0 (en) Therapeutic use
EP1450837A4 (en) INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
GB0316912D0 (en) Therapeutic treatment
GB0324761D0 (en) Use of compounds in therapy
GB0320806D0 (en) Therapeutic treatment
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
GB0314261D0 (en) Therapeutic agents
GB0316237D0 (en) Therapeutic agents
GB0314049D0 (en) Therapeutic agents
GB0219660D0 (en) Therapeutic use
GB0207410D0 (en) Compounds and their therapeutic use
GB0314136D0 (en) Therapeutic agents
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
IL172061A0 (en) Further therapeutic use of zolpidem
GB0322990D0 (en) Therapeutic use
GB0224787D0 (en) Therapeutic use
GB0226865D0 (en) Therapeutic use
GB0226850D0 (en) Therapeutic use
GB0223118D0 (en) Therapeutic use
GB0311457D0 (en) New therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)